HO-1 polymorphism as a genetic determinant behind the malaria resistance afforded by haemolytic disorders

Medical Hypotheses

Volumn 74, Issue 5, 2010, Pages 807-813

  Garcia Santos, D ^a   Chies, J A B ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CD163 ANTIGEN; HAPTOGLOBIN; HEME; HEME OXYGENASE 1; HEMOGLOBIN; HEMOPEXIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; METHEMOGLOBIN; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9;

ALLELE; ARTICLE; DISEASE SEVERITY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HEALTH CARE POLICY; HUMAN; INFECTION RESISTANCE; INFECTION SENSITIVITY; MALARIA; NONHUMAN; PATHOGENESIS; PLASMODIUM MALARIAE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SICKLE CELL ANEMIA; SINGLE NUCLEOTIDE POLYMORPHISM; THALASSEMIA;

ANEMIA, HEMOLYTIC, CONGENITAL; HEME; HEME OXYGENASE-1; HUMANS; IMMUNITY, INNATE; MALARIA; MOLECULAR STRUCTURE; POLYMORPHISM, GENETIC; SELECTION, GENETIC;

EID: 77950940963     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.12.010     Document Type: Article

References (116)

1. Abraham N.G., Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 2008, 60:79-127.
2. Shibahara S., Muller M., Taguchi H. Transcriptional control of rat heme oxygenase by heat shock. J Biol Chem 1987, 262:12889-12892.
3. Mitani K., Fujita H., Sassa S., Kappas A. Heat shock induction of heme oxygenase mRNA in human Hep3B hepatoma cells. Biochem Biophys Res Commun 1989, 165:437-441.
4. Keyse S.M., Tyrrell R.M. Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. Proc Natl Acad Sci USA 1989, 86:99-103.
5. Nascimento A.L., Luscher P., Tyrrell R.M. Ultraviolet A (320-380nm) radiation causes an alteration in the binding of a specific protein/protein complex to a short region of the promoter of the human heme oxygenase 1 gene. Nucleic Acids Res 1993, 21:1103-1109.
6. Stocker R., Yamamoto Y., McDonagh A.F., Glazer A.N., Ames B.N. Bilirubin is an antioxidant of possible physiological importance. Science 1987, 235:1043-1046.
7. Eisenstein R.S., Garcia-Mayol D., Pettingell W., Munro H.N. Regulation of ferritin and heme oxygenase synthesis in rat fibroblasts by different forms of iron. Proc Natl Acad Sci USA 1991, 88:688-692.
8. Prabhakar N.R., Dinerman J.L., Agani F.H., Snyder S.H. Carbon monoxide: a role in carotid body chemoreception. Proc Natl Acad Sci USA 1995, 92:1994-1997.
9. Ollinger R., Yamashita K., Bilban M., et al. Bilirubin and biliverdin treatment of atherosclerotic diseases. Cell Cycle 2007, 6:39-43.
10. Li M., Kim D.H., Tsenovoy P., et al. Treatment of obese diabetic mice with an heme oxygenase inducer reduces visceral and abdominal adiposity increases adiponectin levels and improves insulin sensitivity and glucose tolerance. Diabetes 2008, 57:1526-1535.
11. Juan S.H., Lee T.S., Tseng K.W., et al. Adenovirus-mediated heme oxygenase-1 gene transfer inhibits the development of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2001, 104:1519-1525.
12. Baynes J.W. Role of oxidative stress in development of complications in diabetes. Diabetes 1991, 40:405-412.
13. Zou M.H., Shi C., Cohen R.A. High glucose via peroxynitrite causes tyrosinenitration and inactivation of prostacyclin synthase that is associated with thromboxane/prostaglandin H2 receptor-mediated apoptosis and adhesion molecular expression in cultured human aortic endothelial cells. Diabetes 2002, 51:198-203.
14. Hadi H.A., Carr C.S., Al Suwaidi J. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manage 2005, 1:183-198.
15. Kawamura K., Ishikawa K., Wada Y., et al. Bilirubin from heme oxygenase-1 attenuates vascular endothelial activation and dysfunction. Arterioscler Thromb Vasc Biol 2005, 25:155-160.
16. Dulak J., Loboda A., Zagorska A., Jozkowicz A. Complex role of hemeoxygenase-1 in angiogenesis. Antioxid Redox Signal 2004, 6:858-866.
17. Bussolati B., Mason J.C. Dual role of VEGF-induced heme-oxygenase-1 in angiogenesis. Antioxid Redox Signal 2006, 8:1153-1163.
18. Ndisang J.F., Tabien H.E., Wang R. Carbon monoxide and hypertension. J Hypertens 2004, 22:1057-1074.
19. World Health Organization. Expert committee on malaria: 20th report; 2000 [accessed 2009]. http://www.rbm.who.int/docs/ecr20.pdf.
20. Prudencio M., Rodriguez A., Mota M.M. The silent path to thousands of merozoites: the Plasmodium liver stage. Nat Rev Microbiol 2006, 4:849-856.
21. Schofield L., Grau G.E. Immunological processes in malaria pathogenesis. Nat Rev Immunol 2005, 5:722-735.
22. Haldar K., Murphy S.C., Milner D.A., Taylor T.E. Malaria: mechanisms of erythrocytic infection and pathological correlates of severe disease. Annu Rev Pathol 2007, 2:217-249.
23. Idro R., Jenkins N.E., Newton C.R. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet Neurol 2005, 4:827-840.
24. Miller L.H., Baruch D.I., Marsh K., Doumbo O.K. The pathogenic basis of malaria. Nature 2002, 415:673-679.
25. Ferreira A., Balla J., Jeney V., Balla G., Soares M.P. A central role for free heme in the pathogenesis of severe malaria: the missing link?. J Mol Med 2008, 86:1097-1111.
26. Gazzinelli R.T., Denkers E.Y. Protozoan encounters with Toll-like receptor signalling pathways: implications for host parasitism. Nat Rev Immunol 2006, 6:895-906.
27. Parroche P., Lauw F.N., Goutagny N., et al. Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. Proc Natl Acad Sci USA 2007, 104:1919-1924.
28. Coban C., Ishii K.J., Uematsu S., et al. Pathological role of Toll-like receptor signaling in cerebral malaria. Int Immunol 2007, 19:67-79.
29. Mockenhaupt F.P., Cramer J.P., Hamann L., et al. Toll-like receptor (TLR) polymorphisms in African children: common TLR-4 variants predispose to severe malaria. Proc Natl Acad Sci USA 2006, 103:177-182.
30. Mockenhaupt F.P., Hamann L., von Gaertner C., et al. Common polymorphisms of toll-like receptors 4 and 9 are associated with the clinical manifestation of malaria during pregnancy. J Infect Dis 2006, 194:184-188.
31. Francis S.E., Sullivan D.J., Goldberg D.E. Hemoglobin metabolism in the malaria parasite Plasmodium falciparum. Annu Rev Microbiol 1997, 51:97-123.
32. Jeney V., Balla J., Yachie A., et al. Pro-oxidant and cytotoxic effects of circulating heme. Blood 2002, 100:879-887.
33. Balla J., Jacob H.S., Balla G., Nath K., Eaton J.W., Vercellotti G.M. Endothelial-cell heme uptake from heme proteins: induction of sensitization and desensitization to oxidant damage. Proc Natl Acad Sci USA 1993, 90:9285-9289.
34. Kristiansen M., Graversen J.H., Jacobsen C., et al. Identification of the haemoglobin scavenger receptor. Nature 2001, 409:198-201.
35. Atkinson S.H., Mwangi T.W., Uyoga S.M., et al. The haptoglobin 2-2 genotype is associated with a reduced incidence of Plasmodium falciparum malaria in children on the coast of Kenya. Clin Infect Dis 2007, 44:802-809.
36. Hvidberg V., Maniecki M.B., Jacobsen C., Hojrup P., Moller H.J., Moestrup S.K. Identification of the receptor scavenging hemopexin-heme complexes. Blood 2005, 106:2572-2579.
37. Pamplona A., Ferreira A., Balla J., et al. Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria. Nat Med 2007, 13:703-710.
38. Schluesener H.J., Kremsner P.G., Meyermann R. Heme oxygenase-1 in lesions of human cerebral malaria. Acta Neuropathol (Berl) 2001, 101:65-68.
39. Medana I.M., Mai N.T., Day N.P., et al. Cellular stress and injury responses in the brains of adult Vietnamese patients with fatal Plasmodium falciparum malaria. Neuropathol Appl Neurobiol 2001, 27:421-433.
40. Clark I.A., Awburn M.M., Harper C.G., Liomba N.G., Molyneux M.E. Induction of HO-1 in tissue macrophages and monocytes in fatal falciparum malaria and sepsis. Malar J 2003, 2:41.
41. Chies J.A., Nardi N.B. Sickle cell disease: a chronic inflammatory condition. Med Hypotheses 2001, 57:46-50.
42. Balla J., Vercellotti G.M., Jeney V., et al. Haem, haem oxygenase and ferritin in vascular endothelial cell injury. Nephrol Dial Transplant 2003, 18:v8-v12.
43. Bunn H.F., Jandl J.H. Exchange of heme among hemoglobins and between hemoglobin and albumin. J Biol Chem 1968, 243:465-475.
44. Hebbel R.P., Morgan W.T., Eaton J.W., Hedlund B.E. Accelerated autooxidation and heme loss due to instability of sickle hemoglobin. Proc Natl Acad Sci USA 1988, 85:237-241.
45. Belcher J.D., Mahaseth H., Welch T.E., Otterbein L.E., Hebbel R.P., Vercellotti G.M. Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. J Clin Invest 2006, 116:808-816.
46. Lanaro C., Franco-Penteado C.F., Albuqueque D.M., Saad S.T., Conran N., Costa F.F. Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy. J Leukoc Biol 2009, 85:235-242.
47. Otterbein L.E., Soares M.P., Yamashita K., Bach F.H. Heme oxygenase-1: unleashing the protective properties of heme. Trends Immunol 2003, 24:449-455.
48. Wagener F.A., Volk H.D., Willis D., et al. Different faces of the heme-heme oxygenase system in inflammation. Pharmacol Rev 2003, 55:551-571.
49. Stocker R., McDonagh A.F., Glazer A.N., Ames B.N. Antioxidant activities of bile pigments: biliverdin and bilirubin. Methods Enzymol 1990, 186:301-309.
50. Balla G., Jacob H.S., Balla J., et al. Ferritin: a cytoprotective antioxidant strategem of endothelium. J Biol Chem 1992, 267:18148-18153.
51. Steinberg MH, Forget BG, Higgs DR, et al. Disorders of hemoglobin: genetics, pathophysiology and clinical management. Cambridge, UK: Cambridge University Press; 2001.
52. Vichinsky E.P. Changing patterns of thalassemia worldwide. Ann NY Acad Sci 2005, 1054:18-24.
53. Giardine B., van Baal S., Kaimakis P. HbVar database of human hemoglobin variants and thalassemia mutations: 2007 update. Hum Mutat 2007, 28:206.
54. Taher A.T., Otrock Z.K., Uthman I., Cappellini M.D. Thalassemia and hypercoagulability. Blood Rev 2008, 22:283-292.
55. Aggeli C., Antoniades C., Cosma C., et al. Endothelial dysfunction and inflammatory process in transfusion-dependent patients with betathalassemia major. Int J Cardiol 2005, 105:80-84.
56. Butthep P., Bunyaratvej A., Funahara Y., et al. Alterations in vascular endothelial cell-related plasma proteins in thalassaemic patients and their correlation with clinical symptoms. Thromb Haemost 1995, 74:1045-1049.
57. Butthep P., Rummavas S., Wisedpanichkij R., Jindadamrongwech S., Fucharoen S., Bunyaratvej A. Increased circulating activated endothelial cells, vascular endothelial growth factor, and tumor necrosis factor in thalassemia. Am J Hematol 2002, 70:100-106.
58. Conran N., Costa F.F. Hemoglobin disorders and endothelial cell interactions. Clin Biochem 2009, 42:1824-1838.
59. Flint J., Harding R.M., Boyce A.J., Clegg J.B. The population genetics of the haemoglobinopathies. Baillière's clinical haematology haemoglobinopathies 1993, Baillière Tindall and WB Saunders, London. D.R. Higgs, D.J. Weatherall (Eds.).
60. Clegg J.B., Weatherall D.J. Thalassemia and malaria: new insights into an old problem. Proc Assoc Am Physicians 1999, 111:278-282.
61. Williams T.N., Wambua S., Uyoga S., et al. Both heterozygous and homozygous thalassemias protect against severe and fatal Plasmodium falciparum malaria on the coast of Kenya. Blood 2005, 106:368-371.
62. +-Thalassemia protects children against disease caused by other infections as well as malaria. Proc Natl Acad Sci USA 1997, 94:14736-14741.
63. May J., Evans J.A., Timmann C., et al. Hemoglobin variants and disease manifestations in severe falciparum malaria. JAMA 2007, 297:2220-2226.
64. +-Thalassemia protects African children from severe malaria. Blood 2004, 104:2003-2006.
65. +-thalassaemia on the incidence of malaria and other diseases in children living on the coast of Kenya. PLoS Med 2006, 3:e158.
66. Williams T.N. Red blood cell defects and malaria. Mol Biochem Parasitol 2006, 149:121-127.
67. +-thalassemia protect against malaria?. PLoS Med 2006, 3:e235.
68. +-Thalassemia protects against anemia associated with asymptomatic malaria: evidence from community-based surveys in Tanzania and Kenya. J Infect Dis 2008, 198:401-408.
69. Yamada N., Yamaya M., Okinaga S., Nakayama K., Shibahara S., Sasaki H. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am J Hum Genet 2000, 66:187-195.
70. Kimpara T., Takeda A., Watanabe K., et al. Microsatellite polymorphism in the human heme oxygenase-1 gene promoter and its application in association studies with Alzheimer and Parkinson disease. Hum Genet 1997, 100:145-147.
71. Ono K., Mannami T., Iwai N. Association of a promoter variant of the haem oxygenase-1 gene with hypertension in women. J Hypertens 2003, 21:1497-1503.
72. Ono K., Goto Y., Takagi S., et al. A promoter variant of the heme oxygenase-1 gene may reduce the incidence of ischemic heart disease in Japanese. Atherosclerosis 2004, 173:313-317.
73. McGinnis R.E., Spielman R.S. Insulin gene 5V flanking polymorphism: length of class 1 allele in number of repeat units. Diabetes 1995, 44:1296-1302.
74. Rich A., Nordheim A., Wang A.H.J. The chemistry and biology of left-handed Z-DNA. Annu Rev Biochem 1984, 53:791-846.
75. Naylor L.H., Clark E.M. D(TG)n d(CA)n sequences upstream of the rat prolactin gene form Z-DNA and inhibit gene transcription. Nucleic Acids Res 1990, 18:1595-1601.
76. Delic J., Onclecq R., Moisan-Coppey M. Inhibition and enhancement of eukaryotic gene expression by potential non-B DNA sequences. Biochem Biophys Res Commun 1991, 181:818-826.
77. Chen Y.H., Lin S.J., Lin M.W., et al. Microsatellite polymorphism in promoter of heme oxygenase gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum Genet 2002, 111:1-8.
78. Hirai H., Kubo H., Yamaya M., et al. Microsatellite polymorphism in heme oxygenase-1 gene promoter is associated with susceptibility to oxidant-induced apoptosis in lymphoblastoid cell lines. Blood 2003, 102:1619-1624.
79. Epiphanio S., Mikolajczak S.A., Gonçalves L.A., et al. Heme oxygenase-1 is an anti-inflammatory host factor that promotes murine plasmodium liver infection. Cell Host Microbe 2008, 3:331-338.
80. Lavrovsky Y., Chatterjee B., Clark R.A., Roy A.K. Role of redox-regulated transcription factors in inflammation, aging and age-related diseases. Exp Gerontol 2000, 35:521-532.
81. Dick P., Schillinger M., Minar E., et al. Haem oxygenase-1 genotype and cardiovascular adverse events in patients with peripheral artery disease. Eur J Clin Invest 2005, 35:731-737.
82. Rueda B., Oliver J., Robledo G., et al. HO-1 promoter polymorphism associated with rheumatoid arthritis. Arthritis Rheum 2007, 56:3953-3958.
83. Kobayashi H., Takeno M., Saito T., et al. Regulatory role of heme oxygenase 1 in inflammation of rheumatoid arthritis. Arthritis Rheum 2006, 54:1132-1142.
84. Wagener F.A., Toonen E.J., Wigman L., et al. HMOX1 promoter polymorphism modulates the relationship between disease activity and joint damage in rheumatoid arthritis. Arthritis Rheum 2008, 58:3388-3393.
85. Lo S.S., Lin S.C., Wu C.W., et al. Heme oxygenase-1 gene promoter polymorphism is associated with risk of gastric adenocarcinoma and lymphovascular tumor invasion. Ann Surg Oncol 2007, 14:2250-2256.
86. Courtney A.E., McNamee P.T., Heggarty S., Middleton D., Maxwell A.P. Association of functional haem oxygenase-1 gene promoter polymorphism with polycystic kidney disease and IgA nephropathy. Nephrol Dial Transplant 2008, 23:608-611.
87. Funke C., Tomiuk J., Riess O., Berg D., Soehn A.S. Genetic analysis of heme oxygenase-1 (HO-1) in German Parkinson's disease patients. J Neural Transm 2009, 116:853-859.
88. Chin H.J., Cho H.J., Lee T.W., et al. The heme oxygenase-1 genotype is a risk factor to renal impairment of IgA nephropathy at diagnosis, which is a strong predictor of mortality. J Korean Med Sci 2009, 24:S30-S37.
89. Fu W.P., Zhao Z.H., Fang L.Z., et al. Heme oxygenase-1 polymorphism associated with severity of chronic obstructive pulmonary disease. Chin Med J (Engl) 2007, 120:12-16.
90. Takeda M., Kikuchi M., Ubalee R., et al. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to cerebral malaria in Myanmar. Jpn J Infect Dis 2005, 58:268-271.
91. He J.Q., Ruan J., Connett J.E., Anthonisen N.R., Pare P.D., Sandford A.J. Antioxidant gene polymorphisms and susceptibility to rapid decline in lung function in smokers. Am J Respir Crit Care Med 2002, 166:323-328.
92. Guénégou A., Leynaert B., Bénessiano J. Association of lung function decline with the heme oxygenase-1 gene promoter microsatellite polymorphism in a general population sample. Results from the European Community Respiratory Health Survey (ECRHS), France. J Med Genet 2006, 43:e43.
93. Sheu C.C., Zhai R., Wang Z., et al. Heme oxygenase-1 microsatellite polymorphism and haplotypes are associated with the development of acute respiratory distress syndrome. Intensive Care Med 2009, 35:1343-1351.
94. Kaneda H., Ohno M., Taguchi J., et al. Heme oxygenase-1 gene promoter polymorphism is associated with coronary artery disease in Japanese patients with coronary risk factors. Arterioscler Thromb Vasc Biol 2002, 22:1680-1685.
95. Schillinger M., Exner M., Mlekusch W., et al. Heme oxygenase-1 gene promoter polymorphism is associated with abdominal aortic aneurysm. Thromb Res 2002, 106:131-136.
96. Endler G., Exner M., Schillinger M., et al. A microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with increased bilirubin and HDL levels but not with coronary artery disease. Thromb Haemost 2004, 91:155-161.
97. Lüblinghoff N., Winkler K., Winkelmann B.R. Genetic variants of the promoter of the heme oxygenase-1 gene and their influence on cardiovascular disease (the Ludwigshafen Risk and Cardiovascular Health study). BMC Med Genet 2009, 10:36.
98. Chen Y.H., Chau L.Y., Chen J.W., Lin S.J. Serum bilirubin and ferritin levels link heme oxygenase-1 gene promoter polymorphism and susceptibility to coronary artery disease in diabetic patients. Diabetes Care 2008, 31:1615-1620.
99. Kanai M., Tanabe S., Okada M., et al. Polymorphisms of heme oxygenase-1 and bilirubin UDP-glucuronyltransferase genes are not associated with Kawasaki disease susceptibility. Tohoku J Exp Med 2003, 200:155-159.
100. Schillinger M., Exner M., Mlekusch W., et al. Heme oxygenase-1 genotype is a vascular anti-inflammatory factor following balloon angioplasty. J Endovasc Ther 2002, 9:385-394.
101. Chen Y.H., Chau L.Y., Lin M.W., et al. Heme oxygenase-1 promoter microsatellite polymorphism is associated with angiographic restenosis after coronary stenting. Eur Heart J 2004, 25:39-47.
102. Tiroch K., Koch W., von Beckerath N., Kastrati A., Schömig A. Heme oxygenase-1 gene promoter polymorphism and restenosis following coronary stenting. Eur Heart J 2007, 28:968-973.
103. Exner M., Schillinger M., Minar E., et al. Heme oxygenase-1 promoter microsatellite polymorphism is associated with restenosis after percutaneous transluminal angioplasty. J Endovasc Ther 2001, 8:433-440.
104. Schillinger M., Exner M., Minar E., et al. Heme oxygenase-1 genotype and restenosis after balloon angioplasty: a novel vascular protective factor. J Am Coll Cardiol 2004, 43:950-957.
105. Chin H.J., Cho H.J., Lee T.W., et al. The heme oxygenase-1 genotype is a risk factor to renal impairment of IgA nephropathy at diagnosis, which is a strong predictor of mortality. J Korean Med Sci 2009, 24(Suppl.):S30-S37.
106. Exner M., Bohmig G.A., Schillinger M., et al. Donor heme oxygenase-1 genotype is associated with renal allograft function. Transplantation 2004, 77:538-542.
107. Baan C., Peeters A., Lemos F., et al. Fundamental role for HO-1 in the self protection of renal allografts. Am J Transplant 2004, 4:811-818.
108. Ozaki K.S., Marques G.M., Nogueira E., et al. Improved renal function after kidney transplantation is associated with heme oxygenase-1 polymorphism. Clin Transplant 2008, 22:609-616.
109. Denschlag D., Marculescu R., Unfried G., et al. The size of a microsatellite polymorphism of the haemoxygenase-1 gene is associated with idiopathic recurrent miscarriage. Mol Hum Reprod 2004, 10:211-214.
110. Lo S.S., Lin S.C., Wu C.W., et al. Heme oxygenase-1 gene promoter polymorphism is associated with risk of gastric adenocarcinoma and lymphovascular tumor invasion. Ann Surg Oncol 2007, 14:2250-2256.
111. Okamoto I., Krögler J., Endler G., et al. A microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with risk for melanoma. Int J Cancer 2006, 119:1312-1315.
112. Vashist Y.K., Uzunoglu G., Cataldegirmen G., et al. Heme oxygenase-1 promoter polymorphism is an independent prognostic marker of gastrointestinal stromal tumour. Histopathology 2009, 54:303-308.
113. Kanai M., Akaba K., Sasaki A., Sato M., Harano T., Shibahara S., et al. Neonatal hyperbilirubinemia in Japanese neonates: analysis of the heme oxygenase-1 gene and fetal hemoglobin composition in cord blood. Pediatr Res 2003, 54:165-171.
114. Arredondo M., Jorquera D., Carrasco E., Albala C., Hertrampf E. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with iron status in persons with type 2 diabetes mellitus. Am J Clin Nutr 2007, 86:1347-1353.
115. Gerbitz A., Hillemanns P., Schmid C., et al. Influence of polymorphism within the heme oxygenase-I promoter on overall survival and transplantation-related mortality after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008, 14:1180-1189.
116. Exner M., Minar E., Wagner O., Schillinger M. The role of heme oxygenase-1 promoter polymorphisms in human disease. Free Radic Biol Med 2004, 37:1097-1104.